Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:11 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1105–1128 of 1,351 matching trials from the live ClinicalTrials.gov search.

Filters: New Haven, Connecticut Clear all

Conditions: Healthy
Interventions: PF-06669571; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: HIV Infections
Interventions: Methadone hydrochloride, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1998
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: PF-02341066; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,069 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 140
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Bakersfield, California + 71 more

Conditions: Aortic Valve Stenosis
Interventions: LOTUS Edge Valve System; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 382 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 49
States / cities: Huntsville, Alabama • Tucson, Arizona • Little Rock, Arkansas + 39 more

Conditions: Prostatic Neoplasms
Interventions: Pembrolizumab, Enzalutamide, Placebo; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 28
States / cities: Mobile, Alabama • Fullerton, California • Los Angeles, California + 25 more

Conditions: Healthy
Interventions: PF-07976016, Placebo, Midazolam; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 117 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Schizophrenia
Interventions: Emraclidine 30 mg; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 698 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 62
States / cities: Phoenix, Arizona • Bryant, Arkansas • Little Rock, Arkansas + 46 more

Conditions: Opioid-Related Disorders
Interventions: Experimental feedback, Control feedback, fMRI; Device
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Non-alcoholic Steatohepatitis, Non-alcoholic Fatty Liver Disease
Interventions: Placebo, PF-06865571; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 6
States / cities: Anaheim, California • New Haven, Connecticut • South Miami, Florida + 3 more

Conditions: Failed or Difficult Intubation, Sequela, Intubation;Difficult, Intubation Complication
Interventions: VL Coaching training using C-MAC video laryngoscope; Device
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 22 Years to 70 Years
Enrollment: 1,512 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 8
States / cities: La Jolla, California • Aurora, Colorado • New Haven, Connecticut + 4 more

Conditions: Breast Neoplasms
Interventions: PD-0332991, Letrozole, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 666 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 136
States / cities: Bellflower, California • Beverly Hills, California • Fullerton, California + 83 more

Conditions: Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Synchronous Bilateral Breast Carcinoma, Anatomic Stage I Breast Cancer AJCC v8
Interventions: Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment; Biological · Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 1,056 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2035
U.S. locations: 1160
States / cities: Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 749 more

Conditions: Hypertension, Pulmonary
Interventions: Sotatercept; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2035
U.S. locations: 23
States / cities: Phoenix, Arizona • La Jolla, California • Santa Barbara, California + 20 more

Conditions: Multiple Myeloma
Interventions: Cilta-cel, Pomalidomide, Bortezomib, Dexamethasone, Daratumumab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 419 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 19
States / cities: Birmingham, Alabama • Phoenix, Arizona • Stanford, California + 16 more

Conditions: Parkinson's Disease, Depression
Interventions: Cognitive Behavior Therapy (CBT), Treatment As Usual (TAU); Other
Lead sponsor: Yale University; Other
Eligibility: 40 Years to 80 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: NASH, NAFLD, MASH - Metabolic Dysfunction-Associated Steatohepatitis, Mash, MASH With Fibrosis, MASLD, Fatty Liver Disease, Fatty Liver Disease, Nonalcoholic
Interventions: Digoxin, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 2
States / cities: New Haven, Connecticut

Conditions: Enteral Feeding, Nutrition Disorders
Interventions: Intermittent feed participant, Continuous feeds participant; Dietary Supplement
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Acute Kidney Injury, Peritonitis, Necrotizing Soft Tissue Infection
Interventions: Reltecimod 0.5 mg/kg, Placebo; Drug
Lead sponsor: Atox Bio Ltd; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 40
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 33 more

Conditions: Adolescent Suicide, Adolescent Depression
Interventions: Ketamine Infusion, Midazolam Infusion; Drug
Lead sponsor: Yale University; Other
Eligibility: 13 Years to 17 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Advanced Cancers (Breast, Ovarian, mCRPC, Pancreatic Ductal Adenocarcinoma (PDAC), Brain Mets) With Specific Mutations (Homologous Recombination Deficiency)
Interventions: DSB2455; Drug
Lead sponsor: Duke Street Bio Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 4
States / cities: Sacramento, California • New Haven, Connecticut • New York, New York + 1 more

Conditions: Aortic Stenosis, Mitral Stenosis, Aortic Valve Insufficiency, Mitral Valve Insufficiency, Heart Failure
Interventions: Edwards Aortic and Mitral Bioprostheses Models 11000A and 11000M; Device
Lead sponsor: Edwards Lifesciences; Industry
Eligibility: 18 Years and older
Enrollment: 777 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2026
U.S. locations: 29
States / cities: Birmingham, Alabama • Los Angeles, California • Sacramento, California + 20 more

Conditions: Transthyretin (TTR) Amyloid Cardiomyopathy
Interventions: AI Toolkit for ATTR-CM Diagnosis; Diagnostic Test
Lead sponsor: Yale University; Other
Eligibility: 50 Years to 95 Years
Enrollment: 1,500,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 12
States / cities: San Francisco, California • New Haven, Connecticut • Chicago, Illinois + 9 more

Conditions: Recurrent Osteosarcoma
Interventions: Glembatumumab Vedotin, Laboratory Biomarker Analysis, Pharmacological Study; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Years to 49 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 149
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 90 more

Conditions: Mitral Valve Regurgitation
Interventions: MitraClip™ device implantation, Mitral Valve Repair Surgery; Device · Procedure
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2035
U.S. locations: 63
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 47 more

Search by objective public record fields.

A Study To Understand Safety And Plasma Concentrations Of PF-06669571 During And Following The Oral Administration Of Single And Multiple Doses Of PF-06669571 In Healthy Volunteers Under Fasted And Fed Conditions

Methadone Effects on Zidovudine (ZDV, AZT) Disposition

An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

REPRISE IV: LOTUS Edge Valve System in Intermediate Surgical Risk Subjects

Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)

A Study to Learn How Different Amounts of the Study Medicine Called PF-07976016 Are Tolerated and Act in The Body in Healthy Adults

A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia

Neurofeedback in Individuals With Substance Use Disorders

2-Week Study In People With Nonalcoholic Fatty Liver Disease

Tracheal Intubation Coaching in NICUs

A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)

T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)

A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma

Long Term Follow Up KET-PD

Digoxin In NASH (CODIN)

Intermittent Versus Continuous Enteral Nutrition in Mechanically Ventilated Patients in the Medical Intensive Care Unit

Phase 3 Study of Reltecimod vs Placebo in Patients With Sepsis-associated Acute Kidney Injury

Reducing Adolescent Suicide Risk: Safety, Efficacy, and Connectome Phenotypes of Intravenous Ketamine

Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies

ProspeCtive, nOn-randoMized, MulticENter Clinical Evaluation of Edwards Pericardial Bioprostheses With a New Tissue Treatment Platform (COMMENCE)

An Observational Study Using Artificial Intelligence (AI) Algorithms on Electrocardiography (ECG), Point-of-care Ultrasound (POCUS), and Transthoracic Echocardiophy (TTE) to Estimate the Under-diagnosis of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Across a Diverse Range of US Health Systems.

Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma

MitraClip REPAIR MR Study